129 related articles for article (PubMed ID: 9127745)
1. Optimization of the hydrolysis of conjugated L-DOPA, dopamine and dihydroxyphenylacetic acid in human urine for assay by high-performance liquid chromatography with electrochemical detection.
Tuomainen P; Männistö PT
Eur J Clin Chem Clin Biochem; 1997 Mar; 35(3):229-35. PubMed ID: 9127745
[TBL] [Abstract][Full Text] [Related]
2. Measuring L-dopa in plasma and urine to monitor therapy of elderly patients with Parkinson disease treated with L-dopa and a dopa decarboxylase inhibitor.
Dutton J; Copeland LG; Playfer JR; Roberts NB
Clin Chem; 1993 Apr; 39(4):629-34. PubMed ID: 8472357
[TBL] [Abstract][Full Text] [Related]
3. Method for the determination of gamma-L-glutamyl-L-dihydroxyphenylalanine and its major metabolites L-dihydroxyphenylalanine, dopamine and 3,4-dihydroxyphenylacetic acid by high-performance liquid chromatography with electrochemical detection.
Cummings J; Matheson LM; Smyth JF
J Chromatogr; 1990 Jun; 528(1):43-53. PubMed ID: 2117019
[TBL] [Abstract][Full Text] [Related]
4. In vivo assessment of decarboxylase inhibition or potentiation: urinary dopamine and L-dopa output after L-dopa administration.
Johnson RD; Ruthven CR; Goodwin BL; Sandler M
J Neural Transm; 1976; 38(3-4):181-91. PubMed ID: 956809
[TBL] [Abstract][Full Text] [Related]
5. Determination of tetrahydropapaveroline in the urine of parkinsonian patients receiving L-dopa-carbidopa (Sinemet) therapy by high-performance liquid chromatography.
Cashaw JL
J Chromatogr; 1993 Apr; 613(2):267-73. PubMed ID: 8491812
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.
Andersen AD; Blaabjerg M; Binzer M; Kamal A; Thagesen H; Kjaer TW; Stenager E; Gramsbergen JBP
J Neurochem; 2017 May; 141(4):614-625. PubMed ID: 28244186
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease: the effect of L-dopa therapy on urinary free catecholamines and metabolites.
Davidson DF; Grosset K; Grosset D
Ann Clin Biochem; 2007 Jul; 44(Pt 4):364-8. PubMed ID: 17594783
[TBL] [Abstract][Full Text] [Related]
8. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons.
Atlas D
CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609
[TBL] [Abstract][Full Text] [Related]
9. High-performance liquid chromatographic analysis of S-adenosylmethionine and its metabolites in rat tissues: interrelationship with changes in biogenic catechol levels following treatment with L-dopa.
Wagner J; Danzin C; Huot-Olivier S; Claverie N; Palfreyman MG
J Chromatogr; 1984 May; 290():247-62. PubMed ID: 6736164
[TBL] [Abstract][Full Text] [Related]
10. Rapid procedure for chromatographic isolation of DOPA, DOPAC, epinephrine, norepinephrine and dopamine from a single urinary sample at endogenous levels.
Dalmaz Y; Peyrin L
J Chromatogr; 1978 Jan; 145(1):11-27. PubMed ID: 621235
[TBL] [Abstract][Full Text] [Related]
11. Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy.
Routh JI; Bannow RE; Fincham RW; Stoll JL
Clin Chem; 1971 Sep; 17(9):867-71. PubMed ID: 5571485
[No Abstract] [Full Text] [Related]
12. Iso-homovanillic acid determination in cerebrospinal fluid and in urine during L-DOPA treatment of Parkinson's disease.
Ebinger G; Adriaenssens K
Clin Chim Acta; 1973 Nov; 48(4):427-31. PubMed ID: 4761590
[No Abstract] [Full Text] [Related]
13. Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.
Blandini F; Martignoni E; Pacchetti C; Desideri S; Rivellini D; Nappi G
J Chromatogr B Biomed Sci Appl; 1997 Oct; 700(1-2):278-82. PubMed ID: 9390741
[TBL] [Abstract][Full Text] [Related]
14. Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
Betto P; Ricciarello G; Giambenedetti M; Lucarelli C; Ruggeri S; Stocchi F
J Chromatogr; 1988 Dec; 459():341-9. PubMed ID: 3243910
[TBL] [Abstract][Full Text] [Related]
15. Reduced urinary excretion of dopamine and metabolites in chronic renal parenchymal disease.
Pestana M; Jardim H; Serrão P; Soares-da-Silva P; Guerra L
Kidney Blood Press Res; 1998; 21(1):59-65. PubMed ID: 9661138
[TBL] [Abstract][Full Text] [Related]
16. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
[No Abstract] [Full Text] [Related]
17. Fluorometric method for quantitatively estimating urinary dihydroxyphenylethylamine (dopamine), dihydroxyphenylalanine (dopa), and dihydroxyphenylacetic acid (dopac).
Eichhorn F; Rutenberg A; Kott E
Clin Chem; 1971 Apr; 17(4):296-300. PubMed ID: 5552365
[No Abstract] [Full Text] [Related]
18. MAO and L-dopa treatment of Parkinson's disease.
Tyce GM; Dousa MK; Muenter MD
J Neural Transm Suppl; 1990; 29():233-9. PubMed ID: 2358803
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
20. Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine.
Faraj BA; Lawson DH; Nixon DW; Murray DR; Camp VM; Ali FM; Black M; Stacciarini W; Tarcan Y
Clin Chem; 1981 Jan; 27(1):108-12. PubMed ID: 7004664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
